Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

NDORMS research M Sanni Ali received a Young Investigator Award at this week’s National Osteoporosis Society Conference 2016, held in Birmingham.

Sanni presented work on a non-experimental study using SIDIAP, a real life database from Catalonia, North East Spain. The Prieto-Alhambra Group - Musculoskeletal Pharmaco- and Device epidemiology - at NDORMS evaluated the comparative risk of fragility fracture in type 2 diabetic patients using different anti-diabetic medications.

It is estimated that 415 million people between the ages of 20 and 70 worldwide have diabetes, with the condition expected to affect one person in 10 by 2040 - 642 million. In addition, it is estimated globally that 1 in 2 adults with Type 2 diabetes are undiagnosed.

Sanni said: "We found that the risk of fragility fracture is higher in insulin users compared to patients who are on metformin mono-therapy. This data is very useful to manage the condition in the broader context of a patient's life and hopefully can inform new therapeutic approaches for these patients."

Together with another abstract, Sanni's submitted work to the conference received the highest score from reviewers.

Speaking on the award, Sanni said: "This is a unique conference and I was honoured to meet the world's most influential scientists in the field of osteoporosis. Having my research recognised in such a setting was wonderful and I would like to thank the reviewers and my team for the opportunity."

Similar stories

New centre aims to help companies conduct more efficient trials

Botnar Main Trials

A new clinical therapeutics centre has been set up by the University of Oxford to help life sciences companies identify interventions that have the greatest potential to deliver patient benefit, and so bring down the cost of early phase clinical trials.

Cognitive–behavioural therapy consistently improves quality of life

Main Rehabilitation and self-management Research

A meta-review of the available research into cognitive behavioural therapy reveals it consistently improves health-related quality of life across different medical conditions and demographic populations.

Oxford to collaborate with Janssen to map the cellular landscape of immune mediated disorders

Main Research

The University of Oxford has entered into a strategic collaboration with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

Versus Arthritis Foundation Fellowship awarded to Dr Kristina Zec

Awards Main

Dr Kristina Zec has been awarded a Versus Arthritis Foundation Fellowship to investigate the role of products of lipid oxidation produced by synovial macrophages in triggering articular inflammation.

Study reveals the safety of bisphosphonates in chronic kidney disease

Main

The results of an observational study published in JMBR and funded by the Health Technology Assessment Programme shows that bisphosphonate use is associated with a greater risk of chronic kidney disease progression.

WHiTE Four trial results published

Hip Main OCTRU Orthopaedics and trauma Research

The results of the WHiTE Four clinical trial for the treatment of fragility hip fractures have been published in The Bone and Joint Journal.